{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:40:51Z","timestamp":1787701251978,"version":"build-2784847793"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Fundaci\u00f3 Lluita Contra les Infeccions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"DOI":"10.1093\/jac\/dkae044","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:27:56Z","timestamp":1708626476000},"page":"1193-1194","source":"Crossref","is-referenced-by-count":7,"title":["Early virological failure with cabotegravir\/rilpivirine"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-9314","authenticated-orcid":false,"given":"L","family":"Bail\u00f3n","sequence":"first","affiliation":[{"name":"HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Department of Medicine, Autonomous University of Barcelona , Catalonia , Spain"},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-8972","authenticated-orcid":false,"given":"S","family":"S\u00e1bato","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Coll","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol , Badalona, Barcelona , Spain"},{"name":"Projecte dels Noms-Hispanosida , BCN-Checkpoint, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-7114","authenticated-orcid":false,"given":"J R","family":"Santos","sequence":"additional","affiliation":[{"name":"HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Miranda","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Puig","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"D\u00b4Avolio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-691X","authenticated-orcid":false,"given":"R","family":"Paredes","sequence":"additional","affiliation":[{"name":"HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-1963","authenticated-orcid":false,"given":"J","family":"Molt\u00f3","sequence":"additional","affiliation":[{"name":"HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Negredo","sequence":"additional","affiliation":[{"name":"HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"2024050202510730500_dkae044-B1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"2024050202510730500_dkae044-B2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024050202510730500_dkae044-B3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2 M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024050202510730500_dkae044-B4","doi-asserted-by":"crossref","first-page":"e26006","DOI":"10.1002\/jia2.26006","article-title":"Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study","volume":"25","author":"Garris","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024050202510730500_dkae044-B5","article-title":"Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: results from the Dutch ATHENA national observational cohort","author":"Jongen"},{"key":"2024050202510730500_dkae044-B6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2024050202510730500_dkae044-B7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2024050202510730500_dkae044-B8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024050202510730500_dkae044-B9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fmicb.2019.00655","article-title":"Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain","volume":"10","author":"Delgado","year":"2019","journal-title":"Front Microbiol"},{"key":"2024050202510730500_dkae044-B10","doi-asserted-by":"crossref","first-page":"e29287","DOI":"10.1002\/jmv.29287","article-title":"Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019\u20132021","volume":"95","author":"Vi\u00f1uela","year":"2023","journal-title":"J Med Virol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1193\/57368051\/dkae044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1193\/57368051\/dkae044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T02:51:18Z","timestamp":1714618278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/5\/1193\/7612547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae044","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,22]]}}}